Poor Sleep, Daytime Sleepiness May Lead To Dementia: Read Details Here

Updated Dec 19, 2024 | 08:00 PM IST

SummaryLatest research has established a potential link between poor sleep and the development of dementia, particularly a condition called motoric cognitive risk syndrome (MCR).
Daytime Sleepiness

Daytime Sleepiness (Credit: Canva)

Experiencing daytime sleepiness is something that is usually perceived as a minor inconvenience, but for older adults, it could be an early warning sign of Dementia. This neurodegenerative disease leads to the progressive decline of brain cells. This eventually

affects memory, cognition, and personality, making everyday tasks more difficult. As one of the fastest-growing neurological disorders across the world, dementia poses a significant health threat to ageing populations.

Is Dementia Linked To Poor Sleep?

Daytime sleepiness is a direct result of poor sleep quality. Now, a recent research, published in the journal Neurology, highlighted a potential link between poor sleep and the development of dementia, particularly a condition called motoric cognitive risk syndrome (MCR). The study found that 35.5% of participants who reported extreme daytime sleepiness developed MCR, which is a precursor to dementia.

For this study, researchers followed 445 older adults (average age 76) over three years, aiming to determine whether poor sleep could increase the risk of mild cognitive impairment (MCI), which often leads to dementia. At the start, none of the participants had MCI, but by the end of the study, 36 individuals had developed the condition.

The researchers discovered that participants with poor sleep were more likely to develop MCI compared to those who slept well. However, when depression symptoms were taken into account, the link between poor sleep and MCI became less pronounced, suggesting that while sleep issues are a concern, mental health also plays a key role in dementia risk.

To assess sleep quality, the Pittsburgh Sleep Quality Index (PSQI) was used, evaluating factors such as sleep duration, disturbances, and daytime alertness. Among these, "daytime dysfunction"—defined as excessive sleepiness and low energy during the day—was most strongly associated with an increased risk of MCI. Those experiencing daytime dysfunction were more than three times as likely to develop MCI as those who didn’t report such symptoms.

There are many types of dementia:

Dementia is not a specific disease. According to the Centers for Disease Control and Prevention (CDC), it is an overall term that describes a decline in mental ability that interferes with daily life. People with dementia often have symptoms like trouble remembering, thinking, or making everyday decisions. These symptoms tend to get worse over time.

Alzheimer’s disease is the most common type of dementia, and it mostly affects the elderly. Each form of dementia has a different cause. Though dementia mostly affects older adults, it is not a part of normal ageing. An estimated 6.7 million older adults have Alzheimer's disease in the United States. That number is expected to double by 2060, as per data from the CDC.

In 2022, 3.8% of men and 4.2% women in US were diagnosed with dementia. The percentage of people increase with age from 1.7% for those aged 65-74 to 13.1% for those aged 85 and older. Alzheimer's accounts for 60 to 80% of all dementia cases and it is most prevalent in California, Florida, and Texas, as these states have the highest number of people.

End of Article

​Tpoxx Should No Longer Be Used For Treating Mpox: European Drug Regulator

Updated Apr 1, 2026 | 12:00 AM IST

SummaryThe European Medicines Agency noted that data from four clinical studies showed that Tpoxx did not heal lesions faster, relieve pain, or help clear the virus from the body faster.
​Tpoxx Should No Longer Be Used For Treating Mpox: European Drug Regulator

Credit: Canva/ US CDC

The European Medicines Agency (EMA) has advised patients and physicians not to use the antiviral drug Tecovirimat SIGA (marketed as Tpoxx) to treat mpox disease.

The advisory from the EMA’s Committee for Human Medicines (CHMP) is based on data from four studies carried out in different regions, which showed that compared with placebo treatment with Tpoxx did not

  • heal lesions faster
  • relieve pain
  • help clear the virus from the body faster.
The EMA noted that Tpoxx was authorised for treating mpox in November 2021, based on data from an animal model of mpox infections. At the time, the virus was not circulating widely enough to conduct human studies.

“The animal data demonstrated antiviral activity and a survival benefit when treatment was started early and a reduced efficacy if treatment was initiated later after exposure to the virus,” the EMA said in an official statement.

However, the clade 2 mpox outbreaks, which began in 2022, led the World Health Organization (WHO) to declare mpox a Public Health Emergency of International Concern (PHEIC), giving the drugmaker SIGA Technologies an opportunity to conduct efficacy studies in people.

A second PHEIC was declared in 2024 over clade 1 outbreaks.

Key recommendations by the EMA include:

  • Restricting the use of Tpoxx over no benefit.
  • Due to lack of safety concerns, patients who initiated treatment with Tpoxx can continue till course ends.
  • Tpoxx can still be used as an antiviral to treat other orthopoxvirus infections, including smallpox and cowpox
  • There is currently no other drug authorized in the EU for treating mpox infections.

Tpoxx For Mpox: What Does The US CDC Say

The Centers for Disease Control and Prevention also noted that the role of Tpoxx in treating mpox "is investigational".

The federal agency called for "additional clinical trials" to explore the role of Tpoxx in treating mpox infections in patients with severe immunocompromise, including advanced HIV.

"The findings from the clinical trials suggest that most patients with monkeypox who do not have severe disease or risk factors for severe disease (e.g., severe immunocompromise) will recover with supportive care and pain management," the CDC said.

Also read: Missouri Reports 2 Cases Of Deadly Clade I Mpox, US Tally Rises To 3 In 2026

What Is Mpox?

Mpox, earlier known as monkeypox, is a rare viral disease that belongs to the orthopoxvirus genus, the same family as the more well-known smallpox virus.

Though generally less severe, mpox can still lead to serious health complications, especially in immunocompromised individuals, children, and pregnant women.

The virus is transmitted from animals to humans and can spread from person to person through direct contact with infectious sores, scabs, body fluids, respiratory droplets, or contaminated materials.

Also read: Mpox Outbreak: First Case of Severe Strain Reported in New York City

The earliest signs of mpox start within 14 days of being infected. A person may not know they have mpox and can spread the disease.

The common symptoms include:

  • fever,
  • sweating,
  • chills through the body.
  • rashes, which start as a distant rash on the face and can continue throughout the body,
  • swollen lymph nodes, migraine,
  • muscle aches,
  • fatigue,
  • weakness
  • back pain.

Mpox: Current Cases

In February, a total of 1,184 confirmed mpox cases and four deaths were reported from 46 countries, as per the WHO's latest outbreak update.

Of these cases, 58.6 percent were reported in Africa — mainly from Madagascar, the Democratic Republic of the Congo, Kenya, Burundi, and Liberia.

The WHO said all clades continue to circulate, and transmission of the virus continues mostly within sexual networks, followed by household transmission. All age-groups in some historically endemic areas are being affected.

“Unless mpox outbreaks are rapidly contained and human-to-human transmission is interrupted, there is a risk of sustained community transmission in all settings,” the WHO said.

End of Article

Study Shows Ebola Virus May Persist In Breast Milk For Over 3 Months After Recovery

Updated Mar 31, 2026 | 10:33 AM IST

SummaryIn the 23-year-old woman from Congo, Ebola was still detectable in breast milk at 14 weeks, even though the deadly virus was not found in maternal blood, amniotic fluid, vaginal secretions, or the newborn.
Study Shows Ebola Virus May Persist In Breast Milk For Over 3 Months After Recovery

Credit: Canva

Even after recovery, the deadly Ebola virus (EBOV) can persist for a longer duration — more than three months — in breastmilk, according to a case report.

Ebola virus disease (EVD) is a severe viral illness that has a 25 percent – 90 percent fatality rate.

Ebola in pregnancy raises significant complications ranging from spontaneous abortion to maternal and neonatal death.

In a case report published in the New England Journal of Medicine, a team of researchers from the Republic of Congo and Senegal shared the case history of a 23-year-old woman in whom Ebola was still detectable in breast milk at 14 weeks.

The case reported the rare occurrence of a pregnant woman who survived EVD with no complications, neither to the mother nor the baby. However, the deadly virus was still present in the mothers' breast milk, which cited the potential risk of post-illness transmission to infants.

What Is Ebola Virus Disease?

As per the World Health Organization (WHO), EVD is a rare but severe illness in humans and is often fatal.

People can get infected with the virus if they touch an infected animal when preparing food, or touch body fluids of an infected person such as saliva, urine, feces or semen, or things that have body fluids of an infected person like clothes or sheets.

Ebola enters the body through cuts in the skin or when one is touching their eyes, nose or mouth. Early symptoms include fever, fatigue and headache.

What Was The Case

The woman from the Democratic Republic of the Congo (DRC) contracted EBOV during pregnancy in 2019.

Soon after, she was administered monoclonal antibody therapy and was discharged after three negative reverse-transcriptase–polymerase-chain-reaction blood tests for EBOV.

The woman delivered a healthy baby at 42 weeks of gestation. No evidence of EBOV infection was found in maternal blood, amniotic fluid, vaginal secretions, or the newborn.

Ebola Detectable In Breast Milk At 14 Weeks

Yet surprisingly, the EBOV virus persisted in the placenta and breast milk.

Tests revealed that while the mother’s blood remained negative, viral RNA was still detectable in breast milk at 14 weeks after illness onset. To protect the newborn from transmission, clinicians used the drug bromocriptine to suppress lactation.

As per the World Health Organization (WHO) guidelines, the mother was also isolated from the baby and not breastfed. A prophylactic (preventive) monoclonal antibody was also given to the newborn. During follow-up, the infant exhibited no signs of infection.

Ebola Virus: WHO Guidelines

During the 2018–2020 EVD outbreak in the northeast of DRC, 3,481 confirmed cases were reported. Of these, nearly 60 percent occurred in females, and about 45 percent occurred in children below 18 years of age.

Current WHO guidance recommends that Ebola survivors avoid breastfeeding until viral clearance is confirmed.

The global health body advises women with suspected or confirmed Ebola to immediately stop breastfeeding and be prioritized for diagnostic testing.

Children exposed to Ebola through breast milk

  • Must be placed under care,
  • Closely monitored for symptoms over 21 days
  • Fed with an appropriate breast milk substitute.
  • Restarted on breastfeeding after two consecutive negative tests of breast milk.

End of Article

Meningitis claimed 259,000 lives globally in 2023: The Lancet

Updated Mar 31, 2026 | 08:59 AM IST

SummaryA total of 2.5 million people globally were infected with meningitis, while children accounted for a third of the deaths, many of which were in Africa. Global vaccination campaigns since 2000 have played a significant role in reducing the number of infections and deaths by bacterial meningitis.
Meningitis claimed 259,000 lives globally in 2023: The Lancet

Credit: Canva

Meningitis – the inflammation of the brain and spinal cord lining – has claimed 259,000 lives worldwide in 2023, according to a new study, published in The Lancet Neurology.

A total of 2.5 million people globally were infected with meningitis, which is also the leading infectious cause of neurological disabilities.

Importantly, children accounted for a third of the deaths, many of which were in Africa, according to research that described itself as the most comprehensive global assessment of meningitis yet.

The study comes amidst a “unprecedented” meningitis outbreak in the UK’s Kent, where two people died, and many were infected.

Meningitis: Achieving WHO 2030 goals

According to the study, global vaccination campaigns since 2000, played a significant role in reducing the number of infections and deaths by bacterial meningitis, in both high-income and low-income countries.

The Global Burden of Disease study led by an international team of researchers led by those from the University of Washington, showed that although mortality and incidence have declined significantly since 1990, progress is insufficient to meet the WHO 2030 targets.

The WHO targets a 50 percent reduction in meningitis infections and 70 percent reduction in deaths by 2030. However, a substantial meningitis burden persists. It also lags behind other vaccine-preventable diseases.

The driving factor are:

  • common pathogens such as S pneumoniae and N meningitidis
  • emerging non-bacterial pathogens such as Candida spp
  • drug-resistant fungi.
“Achieving WHO goals will require sustained investment in surveillance, vaccination, maternal screening, and health-system strengthening, especially in high-burden settings,” the researchers said.

Also read: Bacterial Meningitis May Cause Long-term Fatigue, Vision Problems, Raise Suicide Risk: Study

What Is Meningitis?

Meningitis is a serious medical condition that affects the protective membranes covering the brain and spinal cord, the meninges. While fever is not always present, it is usually considered as one of the classic symptoms of meningitis.

It is important to know the varied symptoms, causes, and treatments of meningitis for early diagnosis and proper management of the disease.

Meningitis is an infectious illness that brings about inflammation in the meninges. The most common cause of such inflammation is bacterial or viral infections, though other causes are also possible including fungal, parasitic, or non-infectious causes (autoimmune disease, head injury, or brain surgery).

Meningitis may also be caused by bacterial meningitis, which the Centers for Disease Control and Prevention (CDC) indicates can be so severe and bring about conditions like hearing loss, vision problems, and death if not received on time.

Also read: From Vaping to Worm Attack: 5 Unimaginable Ways to Contract Meningitis

Meningitis: Risk factors

As per the Lancet study, the greatest risk factors for deaths was

  • low birthweight
  • premature birth
  • air pollution (both household and atmospheric).
The study also noted disproportionately high disease burden in low-income countries, particularly in the African meningitis belt, where Nigeria, Chad, and Niger recorded the highest death and infection rates.

Streptococcus pneumoniae, Neisseria meningitidis, non-polio enteroviruses, and other viruses were the leading causes of death, while non-polio enteroviruses caused the most cases.

To achieve further reductions in the disease globally, the researchers called for greater efforts, including:

  • expanding vaccination programs,
  • greater antibiotic stewardship,
  • improving access to care,
  • strengthening diagnostics and monitoring for meningitis.

Also read: Unique Symptoms Of Meningitis That Caused An Outbreak In Kent University

Common Symptoms Of Meningitis

  • Rash
  • Headaches
  • Neck stiffness
  • Fever
  • Drowsiness
  • Nausea or vomiting
  • Increased sensitivity to light.

End of Article